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Retrospective study of human leptospirosis in Malaysia based on microscopic 
agglutination test (MAT) showed 13% overall prevalence of infection for the period 
1983-1998. Results indicated that the prevalence was decreasing in the last five years 
(1994-1998). The prevalence was highest among Indians (16.67%) followed by 
Malays (11.48%) and the least among Chinese (5.88%). The 20-29 year-old group 
showed the highest prevalence of infection (17.13%). Less than 10 year-old group 
showed the least prevalence of infection (5.66%). Generally, many of the cases 
occurred between the ages of 20-50 years. Serological survey based on enzyme-
linked immunosorbent assay (ELISA) showed a high overall prevalence (12.56%) of 
leptospiral infection. Kuala Lumpur showed the highest prevalence (19%) whilst 
Penang recorded the lowest prevalence (6.67%). No significant differences in the 
prevalence between the other states was noted. 
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A comparative study of three serological tests, namely enzyme-linked 
immunosorbent assay (ELISA), microscopic agglutination test (MAT) and indirect 
hemagglutination (IHA), test was carried out to evaluate these tests in the diagnosis 
of human leptospirosis. A total of 3000 serum samples from three groups of people 
were examined. In Group I, IgM and IgG-ELISA were able to detect a number of 
cases in the first sampling before MAT titres were detectable. In the second 
sampling, all samples positive for MAT were also positive for IgM-ELISA. IHA test 
gave positive reactions with only 38% of the samples while all samples were positive 
for ELISA. In Group II, ELISA detected IgM and IgG to leptospires in the samples 
which were negative to MAT. These were samples from patients with clinical signs 
of leptospirosis. 
The polymerase chain reaction (peR) was evaluated as a tool for diagnosis of 
leptospirosis and differentiation of leptospiral strains. Urine samples with as little as 
10 serovar hardjo cells per ml of urine were positive on peR indicating high 
sensitivity of the test. Detection of small number of leptospiral cells in urine by peR 
was an advantage over culture. Random amplification polymorphic DNA (RAPD) 
fingerprinting was applied to differentiate leptospiral strains. Two primers were 
tested for their abilities to generate individual RAPD fingerprints. The DNA profiles 
obtained with each primer were distinct and reproducible. The fingerprint obtained 
could be useful for distinguishing the serovars up to the strain level. Profiles 
obtained revealed genetic heterogeneity between serovars belong to one serogroup. 
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Analysis of leptospiral DNA with restriction enzymes, Hind III, BamH I and 
EeoR I revealed a high heterogeneity between the serovars examined. This high 
heterogeneity may be due to the large genome of the genus Leptospira. No 
relationship was found between the restriction patterns and the species from which 
the isolate was isolated. Similarities were observed among isolates of the same 
serovar. The 10  leptospiral field isolates were assayed for presence of plasmid DNA. 
Only two isolates were found to harbour plasmid DNA. The plasmid profiling 
obtained is of limited epidemiological value for differentiation of leptospiral isolates. 
It appears that human leptospirosis is an endemic infection in Malaysia. The 
findings showed that ELISA was a suitable serological test for diagnosis of 
leptospirosis compared to MAT and IRA tests. On the other hand, the application of 
peR and REA in the diagnosis of leptospirosis would be useful. 
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Kajian retrospektif terhadap leptospirosis manusia di Malaysia berasaskan 
ujian pengaglutinatan mikroskopi (MAn menunjukkan prevalens jangkitan 
keseluruhan 13% untuk tempoh 1983 - 1998. Hasil kajian menunjukkan prevalens 
ini semakin kurang dalam tempoh lima tahun terakhir (1994-1998). Prevalens ini 
paling tinggi di kalangan kaum India (16.67%) diikuti kaum Melayu (11.48%) dan 
paling sedikit di kalangan kaum Cina (5.88%). Kumpulan umur 20-29 menunjukkan 
prevalens jangkitan paling tinggi (17.13%). Kumpulun umur kurang daripada 10 
tahun menunjuk prevalens paling rendah (5.66%). Umumnya, banyak daripada kes 
ini berlaku pada kumpulan umur 20 - 25 tahun. Tinjauan serologi berasaskan asai 
imunoserap terangkai enzim (ELISA) menunjukkan prevalens jangkitan leptospira 
keseluruhan tinggi (12.56%). Kuala Lumpur menunjukkan prevalens paling tinggi 
(19%), manakala Pulau Pinang merekodkan prevalens paling rendah (6.67%). Tiada 
kelainan tererti wujud di antara negeri lain. 
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Suatu kajian perbandingan terhadap tiga ujian serologi, iaitu asai imunoerap 
terangkai enzim (ELISA), ujian pengaglutinatan mikroskopi (MAT), dan ujian 
penghemaglutinatan tak langsung (IRA) telah dijalankan untuk menilai ujian ini 
dalam diagnosis leptospirosis manusia. Sejumlah 3000 sampel serum manusia telah 
diperiksa. Dalam kumpulan I, IgM- dan IgG-ELISA dapat mengesan beberapa kes 
dalam pensampelan pertama, sebelum titer MAT dapat dikesan. Dalam pensampelan 
kedua, kesemua sampel yang positif dengan MAT juga positif dengan IgM-ELISA. 
Ujian IRA memberikan tindak balas positif untuk 38% daripada sampel sahaja, 
sambil kesemua sampel positif dengan ELISA. Dalam kumpulan II, ELISA 
mengesan IgM dan IgG terhadap leptospira dalam sampel yang negatif dengan 
MAT. Ini ialah daripadsa pesakit yang menunjukkan petanda klinikal untuk 
leptospira. 
Tindak balas berangkai polimerase (peR) telah dinilai sebagai alat untuk 
diagnosis leptospirosis dan untuk pembezaan strain leptospira. Sampel urin yang 
mengandungi hanya 10 hardjo sel per ml urin masih positif dalam ujian peR, 
menunjukkan tingginya kepekaan ujian tersebut. Pengesan sejumlah sel yang begitu 
keeiI dalam urin melalui peR memberi ujian ini kelebihan berbanding pengkulturan. 
Penyidikjarian DNA polimorfus penguatan rawak (RAPD) telah diguna untuk 
membezakan strain leptospira. Dua primer telah diuji untuk keupayaannya 
menjanakan sidikjari RAPD individu. Profil DNA yang diperolehi daripada setiap 
primer ini adalah nyata dan boleh dihasil semula. Sidikjari yang diperolehi mungkin 
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berguna untuk membeza serovar sehingga pada aras strain. Profil diperolehi 
menunjukkan keheterogenan genetik di antara serovar daripada satu serokumpulan. 
Analisis DNA leptospira dengan enzim pengehadan, Hind III, BamH I dan 
EcorR I menunjukkan keheterogenan tinggi di antara serovar yang diperiksa. 
Keheterogenan tinggi ini mungkin disebabkan oleh genom besar pada genus 
Leptospira. Tiada perkaitan yang ditemui di antara pola pengehadan dan spesies 
daripada mana pencilan itu diperolehi. Persamaan telah dicerap di kalangan pencilan 
yang serovarnya sarna. Pencilan 10 leptospira liar telah diasaikan untuk kewujudan 
DNA plasmid. Hanya dua pencilan telah ditemui mengandungi DNA plasmid. 
Pemprofilan plasmid yang diperolehi itu mempunyai nilai epidemiologi terhad dalam 
pembezaan pencilan leptospira. 
Nampaknya leptospirosis manusia itu adalah suatu jangkitan endemik di 
Malaysia. Penemuan ini menunjukkan ELISA itu merupakan ujian serologi yang 
sesuai untuk diagnosis leptospirosis berbanding ujian MAT dan IRA. Disebaliknya, 
penggunaan peR dan REA dalam diagnosis leptospirosis adalah memuaskan. 
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Leptospirosis, also known as "march fever" and "mud fever," is an 
important zoonotic disease, with important veterinary and public health impact 
(Dikken and Kmety, 1 978; Gussenhoven et a/., 1 997; Marcos et a/., 1 997). 
Leptospirosis is caused by Leptospira interrogans. Based on immunological tests, 
more than 200 leptospiral seorvars have been identified. The serovars could be 
placed into 23 serogroups (Soltys, 1 979; Woodward et a/., 1 997; Chu et a/., 
1 998). In Malaysia, 38 serovars from 1 3  serogroups have been known to occur 
(Bahaman, 1 988). 
In livestock, the disease causes important economic losses. Although this 
disease is usually mild and often subclinical, it can lead to great losses due to 
abortions, stillbirths, infertility, mastitis, weak progeny, decreased milk 
production, and with certain leptospiral serovars, death (Songer et a/., 1983; 
Thiermann, 1 984; Bey and Johnson, 1 986). 
Leptospiral serovars can infect mammals including man. However, the 
pathogenicity and clinical manifestations of the disease depend on the animal 
